Abstract: The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.
Type:
Grant
Filed:
September 23, 1999
Date of Patent:
March 27, 2001
Assignee:
Aventis Behring GmbH
Inventors:
Gerhard Dickneite, Hubert Metzner, Gerd Zettlmeissl, Ulrich Grundmann, Richard Lathe, Austin Smith, Meng Li
Abstract: The present invention relates to stable preparation forms of a transglutaminase, for example factor XIII, which, after lyophilization, are readily soluble without turbidity. The preparation froms comprise, in addition to the transglutaminase additives selected from the group consisting of D- and/or L-amino acids other than glycine and arginine, their salts, derivatives and homologs, or dimers or oligomers thereof or mixtures thereof, and sugars or sugar alcohols. The formulations may also comprise surface active agents and/or reducing agents. The invention provides processes for preparing stable protein preparations and to the use of the described stable preparation forms for producing pharmaceuticals which are suitable, for example, for treating diseases which are characterized by F XIII deficiency.
Abstract: A procedure for the detection of high virus concentrations in blood plasma and/or blood serum by means of the polymerase chain reaction (PCR) is described, in which the sensitivity of the PCR is restricted by the use of suboptimal nucleic acid extraction, amplification or detection conditions. This procedure is suitable, for example, for the detection of parvovirus DNA in plasma or serum, it being possible to adjust the sensitivity of the PCR such that the parvovirus DNA is only detected in samples whose DNA content is greater than 106 to 107 genome equivalents/ml. The detection of the parvovirus DNA amplification carried out is carried out in the sample by measurements of the fluorescence.
Abstract: A process for determining glycosaminoglycans in antithrombin III (ATIII)-containing solutions by increasing the ionic strength of the AT III-containing solution until the interaction between AT III and glycosaminoglycans is prevented, removing the AT III which has been released from the glycosaminoglycans from the solution, and desalting and determining the glycosaminoglycan which has remained in the solution.